Before a cancer therapeutic is selected for clinical development, the mechanism of action, antitumour activity and dosing parameters must be fully characterised in preclinical animal studies. For some cancer agents, continuous dosing is more efficacious than administration by immediate release methods, such as injections.

This webinar discusses how ALZET® Osmotic Pumps offer continuous dosing to lab animals at controlled rates over extended durations, while achieving maximum efficacy at lower doses. These small, implantable pumps have been used successfully with a wide range of agents, including kinase inhibitors, chemotherapeutics, small molecules, peptides, proteins and oligonucleotides.

Presenter

  • José R Gadea, BS, Senior Product Marketing Manager, DURECT Corporation